|
 | |||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| February 2016 Volume 12 Number 2 | |||||||||||||||||||||||||||||||||||||
| In this issue  Research HighlightsYear in ReviewReviewsPerspectives
| ||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
 | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| YEAR IN REVIEW | Top | ||||||||||||||||||||||||||||||||||||
| Glucocorticoids in 2015: New answers to old problems Sarah A. Jones & Eric F. Morand Published online: 24 December 2015 p73 | doi:10.1038/nrrheum.2015.176 Since glucocorticoids were first used to treat patients with rheumatoid arthritis in 1949, they have become the most common therapy for inflammatory disorders; however, their use is associated with major metabolic adverse events. Here, we review three 2015 reports with clinical and fundamental implications for the use of glucocorticoid therapy in rheumatology. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Systemic lupus erythematosus in 2015: Cellular and metabolic requirements of effector T cells George C. Tsokos Published online: 05 January 2016 p74 | doi:10.1038/nrrheum.2015.178 Key advances in lupus research in 2015 highlight the contribution of T cells to the pathogenesis of the disease. The findings not only shed light on the regulation and activity of these cells, but also suggest several novel therapeutic targets. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Psoriatic arthritis in 2015: Advancement continues in imaging, tight control and new drugs Ignazio Olivieri & Salvatore D'Angelo Published online: 22 January 2016 p76 | doi:10.1038/nrrheum.2015.184 In 2015, a EULAR task force released evidence-based recommendations on the use of imaging in the clinical management of spondyloarthritis, including psoriatic arthritis. These recommendations, together with articles dealing with tight control strategies and use of the IL-17A inhibitor secukinumab, have consolidated progress in the management of psoriatic arthritis. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Inflammation in rheumatology in 2015: New tools to tackle inflammatory arthritis Charles A. Dinarello & Leo A. B. Joosten Published online: 14 January 2016 p78 | doi:10.1038/nrrheum.2015.180 Novel therapies to reduce the progressive and destructive nature of inflammatory joint disease are always welcome, provided that safety is not compromised. Among the many 2015 studies in the field, we highlight a targetable mechanism of uric-acid-induced inflammation in gouty arthritis and the expected efficacy — but unforeseen safety concerns — of anti-IL-17 antibodies. Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| REVIEWS | Top | ||||||||||||||||||||||||||||||||||||
| Genetics of ankylosing spondylitis—insights into pathogenesis Matthew A. Brown, Tony Kenna & B. Paul Wordsworth Published online: 06 October 2015 p81 | doi:10.1038/nrrheum.2015.133 Several genetic associations have been identified in patients with spondyloarthropathies, particularly ankylosing spondylitis (AS). The most recent associations uncovered which involve genes in the IL-17/IL-23 pathway enabled a better understanding of the aetiology of spondyloarthropathies, and informed the use of previously existing drugs to treat patients with these diseases—an example of how translation of hypothesis-free medical research can yield new therapeutic strategies. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Strategies for the prevention of knee osteoarthritis Ewa M. Roos & Nigel K. Arden Published online: 06 October 2015 p92 | doi:10.1038/nrrheum.2015.135 Osteoarthritis (OA) is a chronic condition that is associated with pain and disability. In this Review, Roos and Arden consider the strategies that are available for modification of risk factors contributing to the development of knee OA. Interventions for prevention and early care of knee OA could help to avoid joint-replacement surgery. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Anti-DNA antibodies — quintessential biomarkers of SLE David S. Pisetsky Published online: 19 November 2015 p102 | doi:10.1038/nrrheum.2015.151 Anti-DNA antibodies are serological hallmarks of systemic lupus erythematosus, but many questions remain unanswered regarding their origins and pathological properties, as well as the relative merits of different assay formats. Understanding the mechanisms of DNA binding and pathogenesis relating to anti-DNA antibodies can aid the development of diagnostic and theranostic assays. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| Targeting of proangiogenic signalling pathways in chronic inflammation Sander W. Tas, Chrissta X. Maracle, Emese Balogh & Zoltán Szekanecz Published online: 03 December 2015 p111 | doi:10.1038/nrrheum.2015.164 Proangiogenic signalling pathways are activated in chronic inflammation, but although antiangiogenic treatments are routinely incorporated into cancer therapy, surprisingly few clinical trials have investigated this approach in patients with chronic inflammatory diseases. However, this situation could soon change — a wide range of small-molecule inhibitors with improved specificity, and techniques to target such inhibitors to specific cell types, are currently undergoing clinical and preclinical development. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
| PERSPECTIVES | Top | ||||||||||||||||||||||||||||||||||||
| OPINION Does lipopolysaccharide-mediated inflammation have a role in OA? Zeyu Huang & Virginia Byers Kraus Published online: 10 December 2015 p123 | doi:10.1038/nrrheum.2015.158 Lipopolysaccharide derived from gastrointestinal microbiota contributes to systemic inflammation and obesity. Huang and Kraus propose that lipopolysaccharide is a major risk factor for osteoarthritis (OA), and suggest that therapeutic strategies for the reduction of systemic levels of lipopolysaccharide should be considered for prevention and treatment of OA. Abstract | Full Text | PDF | |||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||
YEAR IN REVIEW:
| *Journal Citation Reports, Thomson, 2014. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology. |
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |
 |
No comments:
Post a Comment
Keep a civil tongue.